Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Fondation Leducq
Article History
Received: 27 June 2021
Accepted: 13 December 2021
First Online: 17 January 2022
Competing interests
: OS received funding from Novo Nordisk to study the potential of chronopharmacology in chronic inflammation. OS is an inventor of three patents targeting chemokines and histones in inflammation.